What's Happening?
The U.S. Food and Drug Administration (FDA) has approved bemotrizinol, the first new sunscreen ingredient for the U.S. market in more than 25 years. This ingredient, already used in Europe, offers protection against both UVA and UVB rays without leaving
the white streaks associated with mineral-based sunscreens. Bemotrizinol will be marketed under the brand name Parsol Shield by DSM Nutritional Products and will be available later this year. The approval follows a streamlined process authorized by Congress in 2020, aimed at updating the FDA's list of safe nonprescription drug ingredients. The ingredient is deemed safe for adults and children over six months old.
Why It's Important?
The approval of bemotrizinol marks a significant advancement in sunscreen technology in the U.S., providing consumers with more effective options for sun protection. This development addresses long-standing concerns about the limitations of existing sunscreen ingredients, which often require combinations to achieve broad-spectrum protection. The introduction of bemotrizinol could lead to increased competition and innovation in the sunscreen market, benefiting consumers with better products. Additionally, it highlights the FDA's efforts to modernize its regulatory processes, potentially paving the way for more timely approvals of other health-related products.
What's Next?
Following its initial release, bemotrizinol will have an 18-month exclusivity period before other manufacturers can use the ingredient. This exclusivity could incentivize further research and development in the sunscreen industry. The FDA's ongoing updates to sunscreen regulations, including proposed measures for stronger UVA protection, suggest that more changes could be forthcoming. These regulatory shifts may encourage manufacturers to develop new formulations that meet higher safety and efficacy standards, ultimately enhancing consumer protection against harmful UV exposure.
